Saturday, February 21, 2026
23.9 C
Bengaluru

7 Transitions in Leadership for Indian Pharma Leaders

The rapid pace of change, which began in 2020 is unrelenting and ongoing. The high-stakes game has made many pharma leaders play defensive, instead of using the crisis to bring in the much-needed transformational changes.

Leaders continue to rely on the traditional time-tested strategies, so that they can avoid the embarrassment of ‘losing’ in this high-stakes game. Most prefer to keep doing something they know to do well. We all like to do what we are good at, and are comfortable with. Most leaders are happy to be ‘nest-building’ and remain in their comfort zones.

There are several research findings, suggesting that to make the transition successfully, leaders must navigate a tricky set of changes in their leadership focus and skills.

Here are the seven shifts that leaders must understand and adapt:

  1. Move from, Specialist to Generalist
  2. Analyst to Integrator
  3. Tactician to Strategist
  4. Bricklayer to Architect
  5. Problem solver to Agenda setter
  6. Warrior to Diplomat, and 
  7. Supporting cast member to the Lead role

Digital Excellence Pharma Academy – DEPA, a joint initiative of CredoWeb and MedicinMan has put together 4 learning modules that will enable pharma professionals to be successful in the New Normal.

Register now on https://www.credoweb.in/discussion/588/7-role-transitions-for-pharma-leaders-key-lessons-from-sanjiv-navangul to listen Deep Bhandari explain the 7 Transitions in Leaders and the Key Lessons from Sanjiv Navangul’s session.

Hot this week

India’s Pharma Renaissance: Private Equity at the Helm

Indian pharmaceuticals have long been known as the “pharmacy...

The ₹5 Snack SKU: A Silent Indian Metabolic Crisis

Executive Summary — The Paradox of Scale In the annals...

Sleep Apnea: Apnimed Pill to Replace CPAP Machine?

In India, where urban sleep debt is rising, obesity...

Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich

When a new cancer drug shows promise, it trends...

From Overuse to Overreaction: Recalibrating India’s C-Section Debate

India’s caesarean section debate is drifting toward polarisation. On one...

Topics

India’s Pharma Renaissance: Private Equity at the Helm

Indian pharmaceuticals have long been known as the “pharmacy...

The ₹5 Snack SKU: A Silent Indian Metabolic Crisis

Executive Summary — The Paradox of Scale In the annals...

Sleep Apnea: Apnimed Pill to Replace CPAP Machine?

In India, where urban sleep debt is rising, obesity...

From Overuse to Overreaction: Recalibrating India’s C-Section Debate

India’s caesarean section debate is drifting toward polarisation. On one...

Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift

In big pharma, leadership changes are rarely impulsive. They...

THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL

How a niche Indian topicals manufacturer outgrew its CDMO...

Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?

Transparency, Trust, and the Problem of “Invisible Evidence” in...
spot_img

Related Articles

spot_imgspot_img